Previous 10 | Next 10 |
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health LOS GATOS, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery a...
ORLANDO, FL / ACCESSWIRE / September 22, 2023 / RedChip Companies will air interviews with Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and Aridis Pharmaceuticals, Inc. (OTC:ARDS) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, September 23, at 7 p.m...
ORLANDO, FL / ACCESSWIRE / September 15, 2023 / RedChip Companies will air interviews with Aridis Pharmaceuticals, Inc. (OTC:ARDS), Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE), and American Resources Corporation (Nasdaq:AREC) on The RedChip Money Report®, a sponsored program on Bloo...
Farmer Brothers Company (FARM) is expected to report $-0.61 for Q4 2023 Aspen Group Inc. (ASPU) is expected to report for Q1 2023 Kaspien Holdings Inc. (KSPN) is expected to report for Q1 2024 AGC Inc ADR (ASGLY) is expected to report for Q2 2023 Shimano Inc. ADR (SMNNY) is expect...
AeroVironment Inc. (AVAV) is expected to report $0.4 for Q1 2024 Jeronimo Martins - S.G.P.S., S.A. ADR (JRONY) is expected to report $0.74 for Q2 2023 TuSimple Holdings Inc. (TSP) is expected to report $-0.63 for Q2 2023 CVR Medical Corp (CRRVF) is expected to report for quarter end 2...
Aridis Pharmaceuticals Inc. (ARDS) is expected to report for Q2 2023
2023-08-02 10:21:35 ET Aridis Pharmaceuticals ( OTC:ARDS ) announced pricing of an offering of 10 million shares and accompanying warrants to purchase up to another 10 million shares of common stock at a combined offering price of $0.20 per share of common stock and accompanying warra...
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the pricing of an offering of 10,000,000 ...
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, w...
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective the...
News, Short Squeeze, Breakout and More Instantly...
Aridis Pharmaceuticals Inc. Company Name:
ARDS Stock Symbol:
NASDAQ Market:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...